Clinical Trials Logo

Clinical Trial Summary

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496844
Study type Interventional
Source University of Arizona
Contact Carol Stuehm
Phone 5206268318
Email carols@email.arizona.edu
Status Recruiting
Phase N/A
Start date April 15, 2018
Completion date November 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02940262 - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy N/A
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Recruiting NCT02254746 - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer N/A
Not yet recruiting NCT03649841 - Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer Phase 2
Enrolling by invitation NCT03503643 - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Not yet recruiting NCT03317392 - Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Phase 1/Phase 2
Terminated NCT02564549 - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca N/A
Active, not recruiting NCT01411332 - Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial N/A
Active, not recruiting NCT01787331 - Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Phase 2
Active, not recruiting NCT02268175 - Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Phase 2
Completed NCT01219790 - ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma Phase 1
Completed NCT01026623 - Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Phase 1/Phase 2
Completed NCT00773656 - Patients Overexposed for a Prostate Adenocarcinoma N/A
Terminated NCT00536991 - Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer Phase 1/Phase 2
Not yet recruiting NCT03581500 - Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Participants With Prostate Cancer Phase 2
Recruiting NCT02744287 - Safety and Activity of Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Phase 1
Recruiting NCT02624518 - 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer Phase 2/Phase 3
Recruiting NCT02285101 - Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors Phase 1
Completed NCT00589472 - Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Phase 2
Active, not recruiting NCT02175212 - Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer Phase 3